Richard Below
Family Medicine · Westlake, OHNPI 1447359377
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $532 and has fallen 90.1% since, to $53 in 2024.
Across 56 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$123
- AbbVie$104
- Novo Nordisk$70
- Johnson & Johnson$56
- Astellas Pharma US Inc$56
- Pfizer$50
- plus $413 from 18 others
What the payments were for
- Food & beverage$873100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 6 | $123 |
| AbbVie | 5 | $104 |
| Novo Nordisk | 5 | $70 |
| Johnson & Johnson | 4 | $56 |
| Astellas Pharma US Inc | 3 | $56 |
| Pfizer | 3 | $50 |
| Amgen | 3 | $49 |
| Lilly USA, LLC | 3 | $43 |
| AstraZeneca | 3 | $39 |
| Boehringer Ingelheim | 3 | $39 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| GSK | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $23 |
| Dexcom, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Novartis | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Merck | 1 | $11 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
How this compares
$873 in reported general payments places this provider in the 60th percentile of 3,983 family medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Donepezil Hcl | 24 | $211 |
| Amlodipine Besylate | 25 | $146 |
| Escitalopram Oxalate | 24 | $143 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 24 | $143 |
| Rosuvastatin Calcium | 24 | $143 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Westlake
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Bradley EverlyMaumee$266K
- Tricia BedrickCuyahoga Falls$259K
- David NeidhardtLima$248K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.